The ADAM17 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the ADAM17 gene has been disrupted across a pool of A-549 cells. This polyclonal configuration offers a versatile loss-of-function model that captures the heterogeneous genetic background of the parental line while eliminating the bottleneck effects of single-cell cloning. The resulting cell population is a powerful tool for investigating ADAM17-dependent shedding events without the confounding presence of wild-type protein, enabling robust analysis of signaling networks that rely on this critical metalloprotease.
The parental A-549 cell line was derived from the lung adenocarcinoma of a 58-year-old Caucasian male and is widely employed as a model for human lung adenocarcinoma. These adherent epithelial cells retain key characteristics of lung cancer, including expression of EGFR and pro-inflammatory cytokines, which are directly linked to ADAM17 substrates. Their well-documented growth kinetics, responsiveness to EGFR ligands, and capacity for autocrine signaling make them an ideal host for studying the functional consequences of ADAM17 ablation in a clinically relevant cancer background.
ADAM17 is a membrane-anchored disintegrin-metalloprotease responsible for the ectodomain shedding of numerous transmembrane proteins. It is activated by upstream regulators such as phorbol esters, ERK MAP kinase, p38 MAP kinase, and the adaptor iRhom2. Upon activation, it cleaves a range of substrates including pro-TNF-??, TGF-??, HB-EGF, amphiregulin, epiregulin, IL-6R, and Notch receptors. Soluble TNF-?? subsequently binds TNFR1/2, triggering downstream NF-??B and MAPK signaling cascades. EGFR ligands released by ADAM17 engage the EGFR, initiating pro-survival and proliferative pathways. Interacting factors such as iRhom1/2 and TIMP3 further modulate ADAM17 trafficking and activity.
In the A-549 context, knockout of ADAM17 abrogates the proteolytic release of these signaling mediators, profoundly disrupting autocrine and paracrine loops. The loss of EGFR ligand shedding impairs EGFR phosphorylation and attenuates downstream ERK and AKT signaling, leading to reduced cell proliferation and migration. Simultaneously, diminished soluble TNF-?? blunts NF-??B activation, thereby reducing the expression of inflammatory genes and altering the tumor microenvironment crosstalk. This model thus provides a clean genetic background to dissect the dual roles of ADAM17 in oncogenic and inflammatory programs within lung cancer cells.
This polyclonal knockout product is optimally suited for a broad range of experimental applications. Researchers can employ it to validate ADAM17 as a therapeutic target by comparing cellular responses to small-molecule inhibitors, to decipher ligand-specific contributions to EGFR transactivation, and to map phospho-signaling networks through quantitative western blotting, phospho-flow cytometry, or ELISA-based detection of shed factors. Functional assays such as migration and invasion studies, coupled with RT-qPCR profiling of downstream transcriptional targets, can delineate the protease??s role in metastatic behavior. Additionally, co-culture systems with immune or stromal cells can explore ADAM17-mediated intercellular communication. For further information or to discuss custom applications, please contact Ascent Research.
